MEDIAN Technologies to propose nomination of Dr. Kapil Dhingra to its Board of Directors

  MEDIAN Technologies to propose nomination of Dr. Kapil Dhingra to its Board
  of Directors

Dr. Kapil Dhingra will bring to the board his strategic expertise, vision, and
 experience of the global biopharma industry with an emphasis on the oncology
                              therapeutic area.

Business Wire

SOPHIA ANTIPOLIS, France -- October 26, 2012

RegulatoryNews:

MEDIAN Technologies (Paris:ALMDT) (ALMDT), a leading medical imaging software
solutions developer, and a service provider for image interpretation and
management in oncology clinical trials, announced today that the Board of
Directors, chaired by Fredrik Brag, CEO, has proposed to appoint Mr. Kapil
Dhingra as a new director for a period of 3 years. This decision was made at
the Board’s meeting on October 4 and will be put on the agenda of the next
shareholders’ meeting.

“Kapil Dhingra will bring us his unique strategic expertise, vision and
experience of the global biopharma industry,” said Fredrik Brag, CEO of MEDIAN
and Chairman. “Kapil hasa vast experience in bringing innovations to the drug
development process in oncology. His knowledge and support will contribute to
further enhance MEDIAN growth strategy, in particular as regards to the
advanced imaging services that we bring to top tiers Pharmas and Biotechs. We
are very proud to have him joining our Board,” Fredrik Brag added.

“Accurate and consistent evaluation of tumors is crucial to the management of
patients with cancer and in clinical trials of new drugs and represents a
major unmet technology need in oncology today,” said Kapil Dhingra. “The
solutions provided by the MEDIAN platform can greatly enhance interpretation
and management of images. The ability to obtain high quality and accurate
lesion assessment in near-real-time can significantly enhance the efficiency
of clinical trials of new drugs.”

Dr. Dhingra founded KAPital Consulting LLC in 2008 to help biotechnology,
pharmaceutical and diagnostic companies realize the clinical and commercial
promise of advances in oncology. From 1999 to 2008, he served in positions of
increasing responsibility at Roche including Vice President, Head, Oncology
Disease Biology Leadership Team, and Head, Oncology Clinical Development.
Prior to joining Roche, he worked in the Oncology Clinical Development Group
at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The
University of Texas M.D. Anderson Cancer Center where he led a successful
laboratory as well as clinical research program.

Throughout his industry career, Dr Dhingra held an active faculty appointment
at Indiana University School of Medicine from 1997 to 1999, and more recently,
at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.

Dr Dhingra holds an M.B., B.S. (equivalent to US M.D.) degree from the All
India Institute of Medical Sciences (AIIMS), and has performed postgraduate
work at the AIIMS, the Lincoln Medical and Mental Health Center (New York
Medical College), Bronx NY and Emory University School of Medicine, Atlanta
GA. He is Board-certified in Internal Medicine and Medical Oncology.

Dr Dhingra is currently an advisor to and/or member of the Board of Directors
of several biotechnology and pharmaceutical companies and organizations. He
has previously served on the Boards of several successful biotech companies,
including Biovex and Micromet, which were acquired by major pharmaceutical
companies.

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging
solutions for diagnosing and monitoring cancer patients in clinical trials and
in routine clinical practice. MEDIAN collaborates with institutes at the
cutting edge of medical imaging, including the French National Institute for
Computer Science and Control (INRIA), the University of Chicago, and the Swiss
Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is
present in the market through direct and indirect sales of its LMS solutions
and through alliances with specialist cancer centers in Europe and the USA.
MEDIAN has a strategic partnership with Quintiles, to offer integrated imaging
services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag
(Current CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of
40, over half of whom work in R&D, and has a US-based subsidiary.

For more information on MEDIAN, please visit: www.mediantechnologies.com

Contact:

MEDIAN Technologies
Fredrik Brag, CEO, +33 4 92 90 65 82
fredrik.brag@mediantechnologies.com
or
Press - ALIZE RP
Caroline Carmagnol, + 33 6 64 18 99 59 // + 33 1 42 68 86 43
caroline@alizerp.com
or
Christian Berg, + 33 1 42 68 86 41
christian@alizerp.com